Stocks Health care ACON
NASDAQ · Health careAclarion, Inc. (ACON)
Aclarion, Inc. brought in $83.8K of revenue over the twelve months to June 30, 2026, up 33.1% from a year earlier. It posted a net loss of $9.2M. In fiscal 2025 capital spending exceeded operating cash flow by $7.2M. At June 30, 2026 it held $16.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Aclarion, Inc. does
Aclarion, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker ACON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $75.7K | -$7.2M | -$13.61 | -$7.2M |
| 2024 | $45.7K | -$7M | -$7,478.90 | -$5.3M |
| 2023 | $75.4K | -$4.9M | -$79,782.00 | -$3.6M |
| 2022 | $60.4K | -$7.1M | -$177,383.79 | n/a |
| 2022 | $60.3K | -$5M | -$948,931.16 | n/a |
Where ACON ranks in Health care
Latest SEC filings
What Aclarion, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 30% to $25.2K versus the same quarter last year; diluted EPS -$1.12 versus -$2.75.
- July 9, 2026
- June 4, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 11% to $21.1K versus the same quarter last year; diluted EPS -$1.34 versus -$9.32.
- April 27, 2026Proxy statement DEF 14A
- April 22, 2026Other event 8-K
- April 3, 2026Preliminary proxy statement PRE 14A
- March 25, 2026Passive stake (5% or more) SCHEDULE 13G
- March 19, 2026
- March 18, 2026Annual report 10-K · period to December 31, 2025Revenue rose 66% to $75.7K versus the prior year; diluted EPS -$13.61 versus -$7,478.90.
Insider trades
What the people running Aclarion, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $125.7K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 17, 2026 | Williams Amanda MDirector | Bought | 5,857 | $16K |
| August 14, 2026 | Gould Gregory ACFO | Bought | 10,000 | $24.5K |
| August 13, 2026 | Ness BrentChief Executive Officer, Director | Bought | 5,234 | $12.1K |
| August 13, 2026 | Neal David KDirector | Bought | 7,500 | $18K |
| August 13, 2026 | Wesemann WilliamDirector | Bought | 2,150 | $5K |
| August 13, 2026 | Bond RyanDirector | Bought | 21,122 | $50.1K |
| June 11, 2026 | Breidbart ScottDirector | Received as pay | 20,000 | - |
| June 11, 2026 | Gould Gregory AChief Financial Officer | Received as pay | 50,000 | - |
| June 11, 2026 | Sequira Amanda MaeDirector | Received as pay | 20,000 | - |
| June 11, 2026 | Bond RyanChief Strategy Officer | Received as pay | 55,000 | - |
Who owns ACON
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| SEG Opportunity Fund, LLC13G, passive | 9.98% | March 25, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 352,892 shares in total, about $914K at the last price.
| Holder | Shares |
|---|---|
| Ness BrentChief Executive Officer, Director | 111,534 |
| Bond RyanDirector | 76,122 |
| Gould Gregory ACFO | 60,000 |
| Neal David KDirector | 30,002 |
| Williams Amanda MDirector | 25,857 |
| Breidbart ScottDirector | 25,664 |
| Wesemann WilliamDirector | 23,713 |
Questions about ACON
What does Aclarion, Inc. do?
Aclarion, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker ACON.
Is Aclarion, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $9.2M on revenue of $83.8K.
How much revenue does Aclarion, Inc. make?
Over the twelve months to June 30, 2026 Aclarion, Inc. reported revenue of $83.8K. That is 33.1% more than a year earlier.
When did Aclarion, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 19, 2026.
Similar companies
Compare ACON with
Follow ACON
Get an email when Aclarion, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ACON: get an email when it filesWhere the numbers come from
Financial figures are the values Aclarion, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.